Kymera Therapeutics Inc. (KYMR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Kymera Therapeutics Inc. (KYMR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

40.09

2.87 (7.71%)

At close: Jan 14, 2025, 3:59 PM

40.12

0.07%

After-hours Jan 14, 2025, 04:38 PM EST

undefined% (undefined)

Bid	32.5
Market Cap	2.60B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.34
PE Ratio (ttm)	-17.13
Forward PE	n/a
Analyst	Buy

Ask	41.16
Volume	840,906
Avg. Volume (20D)	445,716
Open	37.56
Previous Close	37.22
Day's Range	37.50 - 43.01
52-Week Range	26.34 - 53.27
Beta	undefined

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 21, 2020

Employees 184

Stock Exchange NASDAQ

Ticker Symbol KYMR

Website https://www.kymeratx.com

Analyst Forecast

According to 15 analyst ratings, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $56, which is an increase of 39.69% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Kymera Therapeutics Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of $10.67M, reflecting a -77.72% YoY shrinking and earnings per share of -0.83, making a 232.00% increase YoY.

Why Price Moved

1 day ago · Source New

+7.79%

Kymera Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

2 months ago · Source

-3.15%

Kymera Therapeutics shares are trading lower after the company reported worse-than-expected Q3 revenue results.

News

1 month ago · seekingalpha.com

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Kymera Therapeutics' KT-474, partnered with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion of studies expected mid-2026. KT-621, a STAT6 degrader for ...

2 months ago · seekingalpha.com

Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President & CEO Jared ...

2 months ago · zacks.com

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.

2 months ago · zacks.com

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago.

2 months ago · zacks.com

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.